Integration of molecular targeted therapy with radiation in head and neck cancer

Pharmacology and Therapeutics

Volumn 142, Issue 1, 2014, Pages 88-98

  Du, Yu ^a,c   Peyser, Noah D ^a,b   Grandis, Jennifer R ^a,b  

^a University of Pittsburgh School of Medicine   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Tsinghua University   (China)

Author keywords

Clinical trials; Epidermal growth factor receptor; Head and neck squamous cell carcinoma; Molecular targeted therapy; Preclinical models; Radiotherapy

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; ERBIUM; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HYDROXYUREA; LAPATINIB; LINSITINIB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRIPHENYLTETRAZOLIUM; UNINDEXED DRUG; VANDETANIB; ZALUTUMUMAB;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMA CELL; CHEMORADIOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOSENSITIVITY;

CLINICAL TRIALS; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; MOLECULAR TARGETED THERAPY; PRECLINICAL MODELS; RADIOTHERAPY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896717347     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.11.007     Document Type: Review

References (81)

1. D.G. Allan Nimotuzumab: evidence of clinical benefit without rash Oncologist 10 2005 760 761
2. K.K. Ang, Z.Q.E., D.I. Rosenthal, P. Nguyen-Tan, E.J. Sherman, and R.S. Weber et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC) ASCO Annual Meeting Proceedings (Post-Meeting Edition). Chicago, IL Vol. 29 2011 5500
3. F. Arias de la Vega, J. Contreras, M. de Las Heras, A. de la Torre, V. Arrazubi, and I. Herruzo et al. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial Ann Oncol 23 2012 1005 1009
4. L. Bastholt, L. Specht, K. Jensen, E. Brun, A. Loft, and J. Petersen et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck Radiother Oncol 85 2007 24 28
5. C. Bianco, G. Tortora, R. Bianco, R. Caputo, B.M. Veneziani, and R. Caputo et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 2002 3250 3258
6. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
7. J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, C.U. Jones, and R.K. Sur et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
8. J.A. Bonner, N.J. Maihle, B.R. Folven, and T.J. Christianson The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities Int J Radiat Oncol Biol Phys 29 1994 243 247
9. J.A. Bonner, K.P. Raisch, H.Q. Trummell, F. Robert, R.F. Meredith, and S.A. Spencer et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers J Clin Oncol 18 2000 47s 53s
10. A. Bozec, P. Formento, S. Lassalle, C. Lippens, P. Hofman, and G. Milano Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts Br J Cancer 97 2007 65 72
11. A. Bozec, A. Sudaka, J.L. Fischel, M.C. Brunstein, M.C. Etienne-Grimaldi, and G. Milano Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model Br J Cancer 99 2008 93 99
12. A. Bozec, A. Sudaka, N. Toussan, J.-L. Fischel, M.-C. Etienne-Grimaldi, and G. Milano Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model Ann Oncol 20 2009 1703 1707
13. H.D. Brooks, B.S. Glisson, B.N. Bekele, F.M. Johnson, L.E. Ginsberg, and A. El-Naggar et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma Cancer 117 2011 2112 2119
14. F. Caponigro, C. Romano, A. Milano, R. Solla, G. Franchin, and V. Adamo et al. A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck Anticancer Drugs 19 2008 739 744
15. G.J. Cerniglia, J. Karar, S. Tyagi, M. Christofidou-Solomidou, R. Rengan, and C. Koumenis et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 Mol Pharmacol 82 2012 1230 1240
16. C. Chen, M. Kane, J. Song, J. Campana, A. Raben, and K. Hu et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer J Clin Oncol 25 2007 4880 4886
17. P. Chinnaiyan, S. Huang, G. Vallabhaneni, E. Armstrong, S. Varambally, and S.A. Tomlins et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
18. C.H. Chung, K. Ely, L. McGavran, M. Varella-Garcia, J. Parker, and N. Parker et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas J Clin Oncol 24 2006 4170 4176
19. C.H. Chung, and M.L. Gillison Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications Clin Cancer Res 15 2009 6758 6762
20. T. Crombet, M. Osorio, T. Cruz, C. Roca, R. del Castillo, and R. Mon et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients J Clin Oncol 22 2004 1646 1654
21. T. Crombet-Ramos, J. Rak, R. Perez, and A. Viloria-Petit Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody Int J Cancer 101 2002 567 575
22. O. Ekshyyan, Y. Rong, X. Rong, K.M. Pattani, F. Abreo, and G. Caldito et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma Mol Cancer Ther 8 2009 2255 2265
23. J. Folkman Role of angiogenesis in tumor growth and metastasis Seminars in oncology Vol. 29 2002 Elsevier 15 18
24. A.A. Forastiere, H. Goepfert, M. Maor, T.F. Pajak, R. Weber, and W. Morrison et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 2003 2091 2098
25. S. Fu, M. Rivera, E.C. Ko, A.G. Sikora, C.-T. Chen, and H.L. Vu et al. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 as a novel approach to enhance radiotherapy J Cell Sci Ther 1 2011
26. T. Fujita, H. Doihara, K. Washio, K. Kawasaki, D. Takabatake, and H. Takahashi et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells Anticancer Drugs 17 2006 455 462
27. M.G. Fury, N.Y. Lee, E. Sherman, A.L. Ho, S. Rao, and A. Heguy et al. A Phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer Int J Radiat Oncol Biol Phys 87 2013 479 486
28. M.G. Fury, N.Y. Lee, E. Sherman, D. Lisa, K. Kelly, and B. Lipson et al. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer Cancer 118 2012 5008 5014
29. J. Gilbert, M.A. Rudek, M.J. Higgins, M. Zhao, S. Bienvenu, and N. Tsottles et al. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck Clin Cancer Res 18 2012 1735 1742
30. D.J. Givens, L.H. Karnell, A.K. Gupta, G.H. Clamon, N.A. Pagedar, and K.E. Chang et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer Arch Otolaryngol Head Neck Surg 135 2009 1209
31. J.E. Gonzalez, J.F. Barquinero, M. Lee, O. Garcia, and A. Casaco Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells Cancer Biol Ther 13 2012 71 76
32. J.R. Grandis, M.F. Melhem, W.E. Gooding, R. Day, V.A. Holst, and M.M. Wagener et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 1998 824 832
33. J.R. Grandis, and D.J. Tweardy Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer Cancer Res 53 1993 3579 3584
34. J.D. Hainsworth, D.R. Spigel, H.A. Burris III, T.M. Markus, D. Shipley, and M. Kuzur et al. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck Cancer 115 2009 2138 2146
35. J.D. Hainsworth, D.R. Spigel, F.A. Greco, D.L. Shipley, J. Peyton, and M. Rubin et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium Cancer J 17 2011 267 272
36. K. Harrington, A. Berrier, M. Robinson, E. Remenar, M. Housset, and F.H. de Mendoza et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease Eur J Cancer 49 2013 1609 1618
37. K.J. Harrington, I.A. El-Hariry, C.S. Holford, A. Lusinchi, C.M. Nutting, and D. Rosine et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck J Clin Oncol 27 2009 1100 1107
38. C.H. Heath, N.L. Deep, L. Nabell, W.R. Carroll, R. Desmond, and L. Clemons et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma Int J Radiat Oncol Biol Phys 85 2013 1275 1281
39. T. Hoang, S. Huang, E. Armstrong, J.C. Eickhoff, and P.M. Harari Enhancement of radiation response with bevacizumab J Exp Clin Cancer Res 31 2012 37
40. S.-M. Huang, J.M. Bock, and P.M. Harari Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res 59 1999 1935 1940
41. S.-M. Huang, J. Li, E.A. Armstrong, and P.M. Harari Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res 62 2002 4300 4306
42. J. Kao, E.M. Genden, C.T. Chen, M. Rivera, C.C. Tong, and K. Misiukiewicz et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer Cancer 117 2011 3173 3181
43. T.J. Kruser, E.A. Armstrong, A.J. Ghia, S. Huang, D.L. Wheeler, and R. Radinsky et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer Int J Radiat Oncol Biol Phys 72 2008 534 542
44. G.J. Kubicek, R.S. Axelrod, M. Machtay, P.H. Ahn, P.R. Anne, and S. Fogh et al. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies Int J Radiat Oncol Biol Phys 83 2012 1192 1197
45. C.M. Lewis, B.S. Glisson, L. Feng, F. Wan, X. Tang, and I.I. Wistuba et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck Clin Cancer Res 18 2012 1435 1446
46. C. Li, M. Iida, E.F. Dunn, and D.L. Wheeler Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma Radiother Oncol 97 2010 330 337
47. D.T. Lin, K. Subbaramaiah, J.P. Shah, A.J. Dannenberg, and J.O. Boyle Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer Head Neck 24 2002 792 799
48. C.I. Lin, E.E. Whang, D.B. Donner, J. Du, J. Lorch, and F. He et al. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer Mol Cancer Res 8 2010 1217 1226
49. R.G. Martins, U. Parvathaneni, J.E. Bauman, A.K. Sharma, L.E. Raez, and M.A. Papagikos et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial J Clin Oncol 31 2013 1415 1421
50. F. Matsumoto, D.N. Valdecanas, K.A. Mason, L. Milas, K.K. Ang, and U. Raju The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation Anticancer Res 32 2012 3029 3035
51. R. Pai, B. Soreghan, I.L. Szabo, M. Pavelka, D. Baatar, and A.S. Tarnawski Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy Nat Med 8 2002 289 293
52. B. Perez-Ordonez, M. Beauchemin, and R. Jordan Molecular biology of squamous cell carcinoma of the head and neck J Clin Pathol 59 2006 445 453
53. U. Raju, H. Ariga, K. Dittmann, E. Nakata, K.K. Ang, and L. Milas Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib Int J Radiat Oncol Biol Phys 63 2005 520 528
54. U. Raju, O. Riesterer, Z.Q. Wang, D.P. Molkentine, J.M. Molkentine, and F.M. Johnson et al. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways Radiother Oncol 105 2012 241 249
55. K. Rao, S. Kalapurakal, P. Chalasani, K. Robinson, J. Malone, and C. Clausen et al. A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer Cancer Chemother Pharmacol 72 2013 545 552
56. C.P. Rodriguez, D.J. Adelstein, L.A. Rybicki, J.P. Saxton, R.R. Lorenz, and B.G. Wood et al. Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck Head Neck 34 2012 1517 1523
57. K.E. Rusthoven, S.J. Feigenberg, D. Raben, M. Kane, J.I. Song, and N. Nicolaou et al. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer Int J Radiat Oncol Biol Phys 78 2010 1020 1025
58. J.K. Salama, D.J. Haraf, K.M. Stenson, E.A. Blair, M.E. Witt, and R. Williams et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers Ann Oncol 22 2011 2304 2309
59. D. Sano, F. Matsumoto, D.R. Valdecanas, M. Zhao, D.P. Molkentine, and Y. Takahashi et al. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro Clin Cancer Res 17 2011 1815 1827
60. A.J. Schueneman, E. Himmelfarb, L. Geng, J. Tan, E. Donnelly, and D. Mendel et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models Cancer Res 63 2003 4009 4016
61. C. Schutze, A. Dorfler, W. Eicheler, D. Zips, S. Hering, and F. Solca et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma Strahlenther Onkol 183 2007 256 264
62. T.Y. Seiwert, D.J. Haraf, E.E. Cohen, K. Stenson, M.E. Witt, and A. Dekker et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer J Clin Oncol 26 2008 1732 1741
63. H. Sharp, J.C. Morris, C. Van Waes, D. Gius, T. Cooley-Zgela, and A.K. Singh High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers Am J Clin Oncol 31 2008 557 560
64. E.T. Shinohara, A. Maity, N. Jha, and R.A. Lustig Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck Head Neck 31 2009 406 411
65. S. Shintani, T. Zhang, A. Aslam, K. Sebastian, T. Yoshimura, and H. Hamakawa P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines Int J Oncol 29 2006 1111
66. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
67. J. Sivasithamparam, C.A. Visk, E.E. Cohen, and A.C. King Modifiable risk behaviors in patients with head and neck cancer Cancer 119 2013 2419 2426
68. T. Tamatani, N. Takamaru, K. Hara, M. Kinouchi, N. Kuribayashi, and G. Ohe et al. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor κB activity in human oral cancer cells Int J Oncol 42 2013 935
69. C.C. Tong, E.C. Ko, M.W. Sung, J.A. Cesaretti, R.G. Stock, and S.H. Packer et al. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases PLoS One 7 2012 e36979
70. A. Trotti, L.A. Bellm, J.B. Epstein, D. Frame, H.J. Fuchs, and C.K. Gwede et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review Radiother Oncol 66 2003 253 262
71. A.S. Tsao, A.S. Garden, M.S. Kies, W. Morrison, L. Feng, and J.J. Lee et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck J Clin Oncol 24 2006 4163 4169
72. C. Van Waes, C.T. Allen, D. Citrin, D. Gius, A.D. Colevas, and N.A. Harold et al. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 77 2010 447 454
73. J.B. Vermorken, J. Stöhlmacher-Williams, I. Davidenko, L. Licitra, E. Winquist, and C. Villanueva et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Lancet Oncol 14 8 2013 697 710
74. C.N. Weber, G.J. Cerniglia, A. Maity, and A.K. Gupta Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation Cancer Biol Ther 6 2007 156 159
75. L. Wirth, A. Allen, M. Posner, R. Haddad, Y. Li, and J. Clark et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck Ann Oncol 21 2010 342 347
76. W. Xue, E. Meylan, T.G. Oliver, D.M. Feldser, M.M. Winslow, and R. Bronson et al. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma Cancer Discov 1 2011 236 247
77. A. Yadav, B. Kumar, T.N. Teknos, and P. Kumar Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins Mol Cancer Ther 10 2011 1241 1251
78. X.-D. Yang, X.-C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit Rev Oncol Hematol 38 2001 17 23
79. X. Yin, H. Zhang, K. Lundgren, L. Wilson, F. Burrows, and C.G. Shores BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy Int J Cancer 126 2010 1216 1225
80. D.S. Yoo, J.P. Kirkpatrick, O. Craciunescu, G. Broadwater, B.L. Peterson, and M.D. Carroll et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer Clin Cancer Res 18 2012 1404 1414
81. C. Yu, B.B. Friday, J.P. Lai, L. Yang, J. Sarkaria, and N.E. Kay et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways Mol Cancer Ther 5 2006 2378 2387